Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple blood test flag heart risk in rheumatoid arthritis?

NCT ID NCT07760662

Knowledge-focused Sponsor: University of La Laguna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at whether certain markers of oxidative stress in the blood are linked to early signs of heart disease in people with rheumatoid arthritis. Researchers will measure these markers and check for thickening or stiffness in the carotid arteries. The goal is to better understand the connection between inflammation, oxidative stress, and cardiovascular risk in this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If oxidative stress markers are linked to early heart disease in rheumatoid arthritis, this could lead to better screening or new treatments to protect the heart.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients with rheumatoid arthritis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The reference population comprises patients with RA fulfilling the 2010 American College of Rheumatology classification criteria who are treated at Hospital Universitario de Canarias, Santa Cruz de Tenerife, and Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Spain, including patients attending hospital outpatient clinics and referral-area services.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women who are not pregnant or breastfeeding. * Age 18 years or older and younger than 70 years. * Treatment with any disease-modifying antirheumatic drug, including biologic therapies. * For patients receiving oral corticosteroids, a prednisone dose of 10 mg or less that has remained stable for at least one month before study inclusion. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Autoimmune rheumatic disease other than RA, including systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, or polymyositis. Sjögren syndrome associated with RA will not be an exclusion criterion. * Functional class IV RA with complete or substantial disability, including confinement to bed or wheelchair that prevents personal self-care. * History or current presence of inflammatory joint disease other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease. * Estimated glomerular filtration rate below 60 mL/min/1.73 m² or active renal disease. * Pregnancy or breastfeeding. * Evidence of severe uncontrolled concomitant cardiovascular, neurological, pulmonary (including obstructive lung disease), renal, hepatic, endocrine (including diabetes mellitus), or gastrointestinal disease, or any condition considered by the investigator likely to alter the lipid profile. * Body weight greater than 150 kg. * History of alcoholism, drug abuse, or substance misuse within six months before the screening visit. * Statin use will not be an exclusion criterion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular (CV) risk are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular (CV) risk Oxidative stress Rheumatoid arthritis (RA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario de Canarias

    RECRUITING

    Santa Cruz de Tenerife, Canary Islands, 38320, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.